<?xml version='1.0' encoding='utf-8'?>
<document id="30791125"><sentence text="Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial."><entity charOffset="36-47" id="DDI-PubMed.30791125.s1.e0" text="Anastrozole" /><entity charOffset="51-65" id="DDI-PubMed.30791125.s1.e1" text="Levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.30791125.s1.e0" e2="DDI-PubMed.30791125.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30791125.s1.e0" e2="DDI-PubMed.30791125.s1.e1" /></sentence><sentence text="Intravaginal rings (IVRs) are an established option for continuous administration of drugs in women" /><sentence text=" The combination of anastrozole (ATZ) and levonorgestrel (LNG) in an IVR with an intended 4-week wearing period has been considered for long-term treatment of endometriosis-associated pelvic pain"><entity charOffset="20-31" id="DDI-PubMed.30791125.s3.e0" text="anastrozole" /><entity charOffset="33-36" id="DDI-PubMed.30791125.s3.e1" text="ATZ" /><entity charOffset="42-56" id="DDI-PubMed.30791125.s3.e2" text="levonorgestrel" /><entity charOffset="58-61" id="DDI-PubMed.30791125.s3.e3" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e0" e2="DDI-PubMed.30791125.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e0" e2="DDI-PubMed.30791125.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e0" e2="DDI-PubMed.30791125.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e0" e2="DDI-PubMed.30791125.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e1" e2="DDI-PubMed.30791125.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e1" e2="DDI-PubMed.30791125.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e1" e2="DDI-PubMed.30791125.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e2" e2="DDI-PubMed.30791125.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30791125.s3.e2" e2="DDI-PubMed.30791125.s3.e3" /></sentence><sentence text=" A randomized, parallel-group, multicenter phase 2b study to assess the efficacy and safety of different dose combinations in women with symptomatic endometriosis has recently been performed" /><sentence text=" This paper will focus on the investigation of pharmacokinetic (PK) effects of ATZ on LNG using data collected from this study"><entity charOffset="79-81" id="DDI-PubMed.30791125.s5.e0" text="ATZ" /><entity charOffset="86-88" id="DDI-PubMed.30791125.s5.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30791125.s5.e0" e2="DDI-PubMed.30791125.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30791125.s5.e0" e2="DDI-PubMed.30791125.s5.e1" /></sentence><sentence text=" Two hundred sixteen patients were randomized to the treatment group with IVRs releasing LNG 40 μg/day alone or in combination with ATZ 300 μg/day, 600 μg/day, or 1050 μg/day for 12 weeks"><entity charOffset="132-134" id="DDI-PubMed.30791125.s6.e0" text="ATZ" /><entity charOffset="89-91" id="DDI-PubMed.30791125.s6.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30791125.s6.e1" e2="DDI-PubMed.30791125.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30791125.s6.e1" e2="DDI-PubMed.30791125.s6.e0" /></sentence><sentence text=" PK blood samples were taken before dosing and before IVR replacement or removal (days 28, 56, and 84)" /><sentence text=" The primary PK parameter was the plasma concentration in apparent steady state of ATZ and LNG at the end of each IVR wearing period"><entity charOffset="83-85" id="DDI-PubMed.30791125.s8.e0" text="ATZ" /><entity charOffset="91-93" id="DDI-PubMed.30791125.s8.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30791125.s8.e0" e2="DDI-PubMed.30791125.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30791125.s8.e0" e2="DDI-PubMed.30791125.s8.e1" /></sentence><sentence text=" Results of PK analysis demonstrate that ATZ concentrations increased proportionally with increasing dose (geometric mean values of 7"><entity charOffset="41-43" id="DDI-PubMed.30791125.s9.e0" text="ATZ" /></sentence><sentence text="85, 15" /><sentence text="48, and 22" /><sentence text="61 μg/L at 300, 600, and 1050 μg/day nominal release, respectively)" /><sentence text=" All point estimates for LNG concentration in apparent steady state ratios between the mono and combination IVR groups were close to 1, and the 90% confidence interval limits were in the 0"><entity charOffset="25-27" id="DDI-PubMed.30791125.s13.e0" text="LNG" /></sentence><sentence text="80 to 1" /><sentence text="25 range (1" /><sentence text="01 [0" /><sentence text="85-1" /><sentence text="19], 1" /><sentence text="03 [0" /><sentence text="88-1" /><sentence text="20], 0" /><sentence text="94 [0" /><sentence text="80-1" /><sentence text="10])" /><sentence text=" In conclusion, our data indicate there is no evidence of drug-drug interaction of ATZ on LNG"><entity charOffset="83-85" id="DDI-PubMed.30791125.s25.e0" text="ATZ" /><entity charOffset="90-92" id="DDI-PubMed.30791125.s25.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30791125.s25.e0" e2="DDI-PubMed.30791125.s25.e0" /><pair ddi="false" e1="DDI-PubMed.30791125.s25.e0" e2="DDI-PubMed.30791125.s25.e1" /></sentence><sentence text="" /></document>